Theravance Biopharma Inc TBPH
Set alert
17.03 USD 0.00 0.00%
At close · Sep 23
17.63 +0.60 +3.52%
After hours · Sep 23, 4:00 PM ET
17.02 Day range 17.07
13.08 52-week range 21.03
- YTD
- -8.98%
- 1 year
- +58.71%
- Open
- 17.06
- Prev close
- 17.03
- Mkt cap
- 884.18M
- Vol
- 10.02M
- Avg vol
- 680.32K
- EPS
- 1.01
- P/E
- 10.92
- Div yield
- 0.00%
More statistics
- Low
- 17.02
- High
- 17.07
- Forward P/E
- 163.17
- Beta
- 0.25
- Short ratio
- 19.79
- Inst. own
- 96.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2026
- 50-d avg
- 9.19
- 200-d avg
- 8.90
- 1y target
- 13.20
Analyst view
Consensus: none
Price target (mean) 13.20 -22.5% downside
Now 17.03
- Target (low)
- 9.00
- Target (mean)
- 13.20
- Target (high)
- 21.00
Ratings (0m) 5 2 buy · 3 hold · 0 sell
- Strong buy1
- Buy1
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.23 | -0.15 – 0.88 | 0.029 | +693.1% | 27.32M | +55.5% | 3 |
| Next quarter | -0.065 | -0.07 – -0.06 | -0.0941 | +30.9% | 16.10M | +11.0% | 2 |
| Current year | -0.11 | -0.48 – 0.60 | -0.3896 | +71.8% | 72.90M | +27.0% | 3 |
| Next year | 0.965 | 0.83 – 1.10 | -0.11 | +977.3% | 102.95M | +41.2% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 6, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 6, 2024 | TD Cowen | Maintained | Hold | Hold |
| Aug 6, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| May 29, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 12, 2024 | BTIG | Initiated | — | Buy |
| Aug 8, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 9, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 28, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Nov 17, 2022 | SVB Leerink | Maintained | — | Outperform |
| Nov 8, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Jul 25, 2022 | Morgan Stanley | Maintained | — | Underweight |
| May 23, 2022 | SVB Leerink | Initiated | — | Outperform |
| Mar 2, 2022 | Morgan Stanley | Maintained | — | Underweight |
| Feb 24, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 5, 2021 | JP Morgan | Upgrade | Underweight | Neutral |
| Sep 16, 2021 | Morgan Stanley | Maintained | — | Underweight |
| Sep 16, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 16, 2021 | SVB Leerink | Maintained | — | Outperform |
| Aug 25, 2021 | Morgan Stanley | Downgrade | Overweight | Underweight |
| Aug 24, 2021 | Cowen & Co. | Downgrade | Outperform | Market Perform |
| Aug 24, 2021 | SVB Leerink | Maintained | — | Outperform |
| Aug 24, 2021 | Needham | Maintained | — | Buy |
| Aug 24, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Aug 4, 2021 | SVB Leerink | Maintained | — | Outperform |
| Jul 16, 2021 | Morgan Stanley | Maintained | — | Overweight |
| Jun 28, 2021 | SVB Leerink | Maintained | — | Outperform |
| May 13, 2021 | Morgan Stanley | Maintained | — | Overweight |
| May 5, 2021 | Needham | Maintained | — | Buy |